ANAli Nakhaei

Ali Nakhaei

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ali Nakhaei has a total of 37 co-authors. Here are the top co-authors by number of shared publications:

  • Amir Reza Afshari

    Department of Basic Sciences, Faculty of Medicine, Mashhad Medical Sciences, Islamic Azad University, Mashhad, Iran

    2 shared publications
  • Mohammad Jalili-Nik

    Department of Medical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

    2 shared publications
  • Alireza Mohtashami

    Student Research Committee, Faculty of Dentistry, Mashhad University of Medical Sciences, Mashhad, Iran

    1 shared publication
  • Alireza Rahimi

    Material Science and Metallurgy Engineering, Karaj Branch, Islamic Azad University, Karaj, Iran

    1 shared publication
  • Arezoo Omidkhoda

    Student Research Committee, MMS.C., Islamic Azad University, Mashhad, Iran

    1 shared publication
  • Arman Abroumand Gholami

    Neuroscience Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

    1 shared publication

Latest Publications

  • Open Access

    Harnessing Repurposed Drugs to Enhance Temozolomide Efficacy in Glioblastoma

    by Ali Nakhaei, Atefeh Taghavi, Amir R. Afshari, Farzaneh Davoudi, Elaheh Gheybi, Mohammad Jalili‐Nik

    Background: Glioblastoma (GB) is the most aggressive primary malignant brain tumor in adults and remains associated with poor survival despite surgical resection followed by radiotherapy and temozolomide (TMZ) chemotherapy. Intrinsic and acquired resistance to TMZ, including MGMT‐dependent DNA repair and activation of pro‐survival pathways, could decrease treatment efficacy. Drug repurposing offers an attractive strategy to identify agents that may enhance TMZ activity because these drugs already have known pharmacokinetic and safety profiles. This narrative review summarizes the available evidence on repurposed drugs investigated as potential modulators of TMZ response in GB. Recent Findings: A range of repurposed agents, including chloroquine, valproic acid, levetiracetam, metformin, aspirin, amlodipine, atorvastatin, chlorpromazine, melatonin, disulfiram, bortezomib, and verteporfin, have been evaluated in GB models and selected clinical studies. Reported mechanisms include modulation of MGMT expression, autophagy, oxidative stress, apoptosis, DNA‐damage responses, cancer stem‐cell properties, and signaling pathways such as PI3K/AKT/mTOR, AMPK, EGFR, STAT3, ERK1/2, and NF‐κB. Several agents have enhanced TMZ‐associated cytotoxicity in cell culture and animal models. However, clinical evidence remains limited, and the results are inconsistent for some drugs. Blood–brain barrier penetration, achievable intratumoral drug exposure, toxicity, treatment scheduling, and molecular heterogeneity of GB remain major translational challenges. Conclusion: Repurposed drugs may provide useful candidates for improving TMZ‐based therapy in GB. However, most evidence remains preclinical, and further studies are needed to clarify blood–brain barrier penetration, optimal dosing, toxicity, predictive biomarkers, and clinical efficacy. Well‐designed prospective clinical trials are required before these combinations can be incorporated into routine GB treatment.

  • Gut Microbiome Strategies for Enhancing ICI Delivery Across the BBB in Glioblastoma

    by Sama Barati, Sahar Ghoflchi, Ali Nakhaei, Mahla Palizkaran Yazdi, Pejman Hosseinzadeh, Hossein Hosseini, Mohammad Jalili‐Nik

    Glioblastoma (GB) is highly malignant with a median survival of 14 months despite conventional treatments like surgery, radiotherapy, and temozolomide. Resistance to these therapies necessitates innovative approaches, such as immune checkpoint inhibitors (ICIs) targeting cytotoxic T‐lymphocyte‐associated protein 4 (CTLA‐4), programmed cell death protein 1 (PD‐1), and programmed death ligand 1 (PD‐L1) to enhance T‐cell‐mediated tumor destruction. However, clinical trials have shown limited ICI efficacy in GB due to its immunosuppressive microenvironment and the blood–brain tumor barrier (BBTB), which impairs drug delivery. Emerging evidence highlights the gut microbiota as a pivotal modulator of ICI response, enhancing CD8 + and CD4 + T‐cell function, antigen presentation, and immune modulation via the gut‐brain axis in cancers. In addition, studies showed that gut‐derived metabolites, including short‐chain fatty acids, modulate immune responses and support blood–brain barrier integrity by regulating inflammatory signaling and tight junction proteins. Future GB research should prioritize clinical trials, mechanistic studies, and interventional strategies like fecal microbiota transplantation and probiotics to enhance ICI efficacy.


  • Open Access

    Anti-Tumor Mechanisms of Calotropis procera in Cancer: A Comprehensive Review

    by Ali Nakhaei, Arezoo Omidkhoda, Sadaf Afshari, Alireza Mohtashami, Mohammad Jalili-Nik, Mahsa Jalali, Seyed Sajad Ahmadi, Amir R. Afshari

    Understanding processes that underlie cancer initiation, progression, and maintenance requires perceiving its distinct features. These characteristics serve as a roadmap for creating innovative treatment approaches that target the core characteristics of cancer, leading to more specialized treatments that may have longer-lasting effects but fewer side effects. Medicinal plants are becoming increasingly prevalent worldwide because of their widely acknowledged safety, affordability, and therapeutic potential. They include naturally occurring chemicals that are highly effective in herbal medicine for some cancer-related processes, such as prevention, mutagenesis suppression, antioxidant defense, and cell proliferation inhibition. The Calotropis procera is one recommended target for cancer treatment. Numerous cellular interactions in both healthy growth and illness were regulated by C. procera. In addition, recent research has elucidated the distinct anticancer activities of C. procera and their relationships with other cellular pathways. These benefits have increased expectations for the development of an effective treatment plan for all types of cancer, particularly the breast, prostate, colorectal, and glioblastoma multiforme cancers.

  • Open Access

    Effect of Intracerebral Hemorrhage on Anxiety and Depression-Like Behavior and Amygdala Glial Changes and Cell Death

    by Mona Riyahi Rad, Shima Shirzad, Atiyeh Ghorbani, Reyhane Vardiyan, Zahra Akhoond-Ali, Mohamad Gharehbaghi, Fatemeh Forouzanfar, Ali Nakhaei, Hossein Akhtar, Alireza Rahimi, et al.

    Introduction: Intracerebral hemorrhage (ICH) is a cerebrovascular disease with a high mortality and morbidity rate. The study aimed to investigate the relationship between amygdala and striatum changes and neuronal and glial changes post-stroke, as over two-thirds of stroke patients experience depression and anxiety. Methods: The study involved 48 male Wistar rats, divided into six groups, including three sham (sham-7, sham-14, and sham-21) and three ICH (ICH-7, ICH-14, and ICH-21) groups. Behavior tests, such as the elevated maze test (EMT), open field test (OFT), and forced swimming test (FST), were used on the 7th, 14th, and 21st days following surgery. Next, the stereology technique was utilized to assess the neuronal density. Finally, the immunohistochemistry method was employed to evaluate alterations in astrocytes. Results: The results indicated that the immobility time, according to FST, was significantly increased on the 21st day after ICH induction. Although the active time in this group decreased compared to the sham-21 group, based on the EMT, the time spent in the closed arm in the ICH-14 and ICH-21 groups had a significant upward trend. According to OFT, central crossing in the ICH-21 group demonstrated a considerable decrease. Nonetheless, neuronal density in the amygdala area displayed no significant differences between the groups. Eventually, glial fibrillary acidic protein-positive cells in the ICH-7 and ICH-21 groups were increased in the ipsilateral amygdala. Conclusion: The results revealed that anxiety and depression behaviors occur 21 days after unilateral ICH is created in the striatum, possibly because the striatum-to-amygdala pathways are affected.

  • Open Access

    The Efficacy of a Combination of Cinnamomum zeylanicum , Tribulus terrestris , Silybum marianum , and Trigonella foenum-graecum as the Treatment of Type II Diabetes Mellitus: A Double-Blinded, Randomized Clinical Trial

    by Seyed Abbas Zojaji, Seyed Ali Ebrahimi, Mokhtar Ahmadi, Elahe Karazhian, Faegheh Zojaji, Mohammad Reza Tabasiyan, Sajjad Samieefar, Seyed Hadi Mousavi, Ali Nakhaei, Mahta Mirshojaiyan

    Introduction: The best oral medication for type II diabetes mellitus (T2DM), metformin, and other T2DM medications have noticeable side effects. However, herbal medications are potential emerging treatments. Thus, this clinical study evaluated the efficacy of a combination of Cinnamomum zeylanicum, Tribulus terrestris, Silybum marianum, and Trigonella foenum-graecum in treating T2DM. Methods: This randomized clinical trial was performed on 50 T2DM patients with hemoglobin A1c (HbA1c)≥6.5% and fasting blood sugar (FBS)≥126 mg/dL who only used metformin as T2DM medication in Imam-Reza Hospital, Mashhad, Iran, in 2017. They were randomly divided into intervention (n=25) and control (n=25) groups. Sealed envelopes were used to blind patients and researchers. Patients were requested to take one capsule twice a day before lunch and dinner for a period of two months. Then, serum HbA1c, FBS, total cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL), triglyceride (TG), aspartate transaminase (AST), alanine transaminase (ALT), blood urea nitrogen (BUN), and creatinine were examined at the beginning of the study and two months later. Results: Seven subjects in the control group were lost during the follow-up. Eventually, 43 patients were evaluated. Twenty-five (58.10%) participants were women, and the mean age of the study population was 57.56±10.51 years old. In the intervention group, FBS was 175.04±34.42 mg/dL before treatment and reached 138.40±26.17 mg/dL after two months (P=0.00). Similarly, HbA1c, cholesterol, LDL, TG, AST, ALT, and BUN were significantly decreased after the intervention, while HDL increased (P=0.00). Creatinine, however, demonstrated no significant change. None of the other measured parameters showed a significant difference in the control group after two months (P>0.05). Conclusion: The suggested herbs could successfully control the glycemic and lipid profiles of T2DM.